- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (228)
- Breast Cancer (710)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (4)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (98)
- Ovarian Cancer (172)
- Pancreatic Cancer (166)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (54)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (620)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (224)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (880)
- Research (384)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (596)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (324)
- Symptoms (182)
- Treatment (1762)
MD Anderson announces 2022 class of Andrew Sabin Family Fellows
2 minute read | Published October 06, 2022
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on October 06, 2022
HOUSTON― The University of Texas MD Anderson Cancer Center has named 10 early career faculty members to the 2022 class of Andrew Sabin Family Fellows. Established by philanthropist Andrew Sabin through a generous $30 million endowment in 2015, the Sabin Family Fellowship program encourages creativity, innovation and impactful cancer research at MD Anderson in the areas of basic science, clinical, physician-scientist and population and quantitative science.
“Up-and-coming faculty members, such as these, are uniquely positioned to launch and to advance practice-changing research,” said Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors.
“They represent some of the best minds in the world, taking on novel, high-risk and high-reward research that can be rapidly translated into clinical solutions for MD Anderson’s patients. It is a privilege to provide the support they need to take their research to the next level.”
Each Sabin Family Fellow will receive $100,000 over two years. This funding frees young researchers to pursue potentially practice-changing science early in their careers when federal and private funding opportunities often are limited.
Finalists were selected through a rigorous external peer-review process. A panel of 25 internationally renowned experts participated in the review of the applications. The 2022 class of Sabin Family Fellows is:
Basic/Translational Scientists
- May Daher, M.D., assistant professor, Stem Cell Transplantation and Cellular Therapy
- Matthew Gubin, Ph.D., assistant professor, Immunology
- Humam Kadara, Ph.D., associate professor, Translational Molecular Pathology
Clinical Researchers
- Van Morris, M.D., associate professor, Gastrointestinal Medical Oncology
- Anaeze Offodile, M.D., assistant professor, Plastic Surgery
- Paolo Strati, M.D., assistant professor, Lymphoma and Myeloma
Physician-Scientists
- Jennifer McQuade, M.D., assistant professor, Melanoma Medical Oncology
- Rahul Sheth, M.D., associate professor, Interventional Radiology
Population/Quantitative Scientists
- Veronika Fedirko, Ph.D., associate professor, Epidemiology
- Nahuriko Ikoma, M.D., assistant professor, Surgical Oncology
Since the fellowship’s establishment, 62 Sabin Family Fellows have been named for their distinction and innovation in their respective fields. The work of the Sabin Family Fellows spans the cancer care continuum, from basic science to translational research to survivorship, and is already impacting the lives of patients at MD Anderson.
“The Andrew Sabin Family Foundation’s exceptional generosity continues to touch many lives as our fellows work to dramatically improve outcomes for those who have been impacted by cancer,” said President Peter WT Pisters, M.D. “We are deeply appreciative of this ongoing partnership which decisively advances MD Anderson's efforts in Making Cancer History®.”

Top row: May Daher, M.D.; Matthew Gubin, Ph.D.; Humam Kadara, Ph.D.; Van Morris, M.D.; Anaeze Offodile, M.D.
Bottom Row: Paolo Strati, M.D.; Jennifer McQuade, M.D.; Rahul Sheth, M.D.; Veronika Fedirko, Ph.D.; Nahuriko Ikoma, M.D.